| scholarly article | Q13442814 |
| P2093 | author name string | Petersen KF | |
| Sullivan JT | |||
| P433 | issue | 11 | |
| P921 | main subject | glucagon | Q28163629 |
| P304 | page(s) | 2018-2024 | |
| P577 | publication date | 2001-11-01 | |
| P1433 | published in | Diabetologia | Q5270140 |
| P1476 | title | Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans | |
| P478 | volume | 44 |
| Q37884060 | A survey of small molecule glucagon receptor antagonists from recent patents (2006 - 2010). |
| Q34387308 | Activation of calcium/calmodulin-dependent protein kinase II in obesity mediates suppression of hepatic insulin signaling. |
| Q26830274 | Addressing unmet medical needs in type 2 diabetes: a narrative review of drugs under development |
| Q35952381 | Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery |
| Q38988157 | Angptl4 does not control hyperglucagonemia or α-cell hyperplasia following glucagon receptor inhibition |
| Q34490178 | Anti-diabetic efficacy and impact on amino acid metabolism of GRA1, a novel small-molecule glucagon receptor antagonist |
| Q37141727 | Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus |
| Q37360316 | Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes |
| Q37199333 | Beyond insulin replacement: addressing the additional needs of the diabetes patient |
| Q36575421 | Biologic actions and therapeutic potential of the proglucagon-derived peptides |
| Q28279881 | Choline supplementation promotes hepatic insulin resistance in phosphatidylethanolamine N-methyltransferase-deficient mice via increased glucagon action |
| Q52674221 | Chronic fractalkine administration improves glucose tolerance and pancreatic endocrine function. |
| Q84417668 | Chronic treatment with a glucagon receptor antagonist lowers glucose and moderately raises circulating glucagon and glucagon-like peptide 1 without severe alpha cell hypertrophy in diet-induced obese mice |
| Q37860396 | Current and emerging antiglycaemic pharmacological therapies: the renal perspective |
| Q37260041 | Current insights and new perspectives on the roles of hyperglucagonemia in non-insulin-dependent type 2 diabetes |
| Q78059436 | Current literature in diabetes |
| Q64921468 | Current perspective on the role of insulin and glucagon in the pathogenesis and treatment of type 2 diabetes mellitus. |
| Q33928941 | Current therapies and emerging drugs in the pipeline for type 2 diabetes |
| Q90650682 | Discovery of Novel Glucagon Receptor Antagonists Using Combined Pharmacophore Modeling and Docking |
| Q35585071 | Dual mode of glucagon receptor internalization: role of PKCα, GRKs and β-arrestins |
| Q42501816 | Ectopic expression of glucagon receptor in skeletal muscles improves glucose homeostasis in a mouse model of diabetes. |
| Q42599817 | Effects of small interfering RNA-mediated hepatic glucagon receptor inhibition on lipid metabolism in db/db mice. |
| Q34381281 | Emerging treatment options for type 2 diabetes |
| Q50156613 | Evidence of a liver-alpha cell axis in humans: hepatic insulin resistance attenuates relationship between fasting plasma glucagon and glucagonotropic amino acids |
| Q51056430 | First proof of pharmacology in humans of a novel glucagon receptor antisense drug. |
| Q44896352 | Future targets in the treatment of type 2 diabetes |
| Q93551696 | G Protein-Coupled Receptors |
| Q39451553 | GLP-1/glucagon receptor co-agonism for treatment of obesity. |
| Q38838119 | Glucagon actions on the kidney revisited: possible role in potassium homeostasis. |
| Q37880234 | Glucagon antagonism as a potential therapeutic target in type 2 diabetes |
| Q36158732 | Glucagon as a target for the treatment of Type 2 diabetes |
| Q33283676 | Glucagon receptor antagonism improves islet function in mice with insulin resistance induced by a high-fat diet |
| Q48171528 | Glucagon receptor as a drug target: A witches' brew of eye of newt (peptides) and toe of frog (receptors). |
| Q39003343 | Glucagon receptor inhibition normalizes blood glucose in severe insulin-resistant mice. |
| Q79387626 | Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia |
| Q34526968 | Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice |
| Q93499036 | Glucagon, glucagon-like peptide and secretin |
| Q41982493 | Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice |
| Q38817842 | Glucagon: acute actions on hepatic metabolism. |
| Q34244209 | Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover |
| Q34328200 | Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors |
| Q34506664 | Human monoclonal antibodies against glucagon receptor improve glucose homeostasis by suppression of hepatic glucose output in diet-induced obese mice |
| Q35669308 | Incretins, insulin secretion and Type 2 diabetes mellitus |
| Q38449296 | Inhibiting or antagonizing glucagon: making progress in diabetes care |
| Q27680518 | Inhibitory Mechanism of an Allosteric Antibody Targeting the Glucagon Receptor |
| Q33808713 | Insulin and glucagon regulate pancreatic α-cell proliferation |
| Q36516806 | Intra-islet glucagon secretion and action in the regulation of glucose homeostasis |
| Q30426407 | Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy? |
| Q47625288 | Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes |
| Q37372130 | Juxtamembranous region of the amino terminus of the family B G protein-coupled calcitonin receptor plays a critical role in small-molecule agonist action |
| Q36437496 | Keynote review: allosterism in membrane receptors |
| Q37412849 | Long-term hyperglucagonaemia induces early metabolic and renal phenotypes of Type 2 diabetes in mice |
| Q36192991 | Maintenance of the postabsorptive plasma glucose concentration: insulin or insulin plus glucagon? |
| Q35762651 | Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes |
| Q24604062 | Molecular basis for negative regulation of the glucagon receptor |
| Q38203645 | Nutrient regulation of glucagon secretion: involvement in metabolism and diabetes. |
| Q33997146 | Pancreatic neuroendocrine tumors in glucagon receptor-deficient mice |
| Q27027920 | Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease |
| Q34452524 | Proglucagon-derived peptides: mechanisms of action and therapeutic potential |
| Q28085593 | Protein- and diabetes-induced glomerular hyperfiltration: role of glucagon, vasopressin, and urea |
| Q35062439 | Recent Progress in the Use of Glucagon and Glucagon Receptor Antago-nists in the Treatment of Diabetes Mellitus |
| Q47190965 | Regulation of amino acid metabolism and alpha cell proliferation by glucagon |
| Q39450184 | Regulation of hepatic glucose metabolism in health and disease |
| Q34370839 | Regulation of net hepatic glycogenolysis and gluconeogenesis during exercise: impact of type 1 diabetes |
| Q51308307 | Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes. |
| Q83824710 | Single dose glucagon (0.5 mg IV bolus) administration in healthy human volunteers is a robust model for assessment of glycogenolysis: characterisation of the glucose excursion after glucagon challenge |
| Q35643168 | Site of action of a pentapeptide agonist at the glucagon-like peptide-1 receptor. Insight into a small molecule agonist-binding pocket |
| Q38398128 | Small molecule glucagon receptor antagonists: a patent review (2011 - 2014). |
| Q36514704 | Targeting glucagon receptor signalling in treating metabolic syndrome and renal injury in Type 2 diabetes: theory versus promise |
| Q38925481 | Targeting hepatic glucose metabolism in the treatment of type 2 diabetes |
| Q30486707 | The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors |
| Q38919742 | The New Biology and Pharmacology of Glucagon. |
| Q37977335 | The alpha-cell as target for type 2 diabetes therapy. |
| Q38162978 | The central question of type 2 diabetes |
| Q37913523 | The role of dysregulated glucagon secretion in type 2 diabetes |
| Q38305508 | Two novel glucagon receptor antagonists prove effective therapeutic agents in high-fat-fed and obese diabetic mice |
| Q35094140 | β2-adrenergic regulation of stress hyperglycemia following hemorrhage in the obese Zucker rat. |
Search more.